ACCELERON PHARMA INC.

(XLRN)
slotkoers Nasdaq  -  19-11-2021
178.75 USD   -0.52%
2021Merck rondt overname Acceleron Pharma af
MT
2021Merck rondt overnamebod in contanten op Acceleron Pharma af voor $180/aandeel
MT
2021Merck breidt overnamebod op Acceleron Pharma uit
MT
OverzichtKoersenGrafiekenNieuwsRatingsOnderneming 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiële publicatiesSectornieuws
Communiqués de presse de la société ACCELERON PHARMA INC.
2021ACCELERON PHARMA : Completion of Acquisition or Disposition of Assets - Form 8-K
PU
2021ACCELERON PHARMA INC : Completion of Acquisition or Disposition of Assets, Notice of Delis..
AQ
2021Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.
AQ
2021Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's Inadequate Offer
BU
2021Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Ten..
BU
2021Acceleron Reports Third Quarter 2021 Financial Results - Form 8-K
PU
2021ACCELERON : Q3 Earnings Snapshot
AQ
2021ACCELERON PHARMA INC Management's Discussion and Analysis of Financial Condition and R..
AQ
2021Acceleron Reports Third Quarter 2021 Financial Results
BU
2021Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension o..
AQ
2021Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders
BU
2021ACCELERON PHARMA INC : Results of Operations and Financial Condition (form 8-K)
AQ
2021Acceleron Announces Third Quarter 2021 REBLOZYL® Net Sales
BU
2021ACCELERON INVESTOR ALERT BY THE FORM : Kahn Swick & Foti, LLC Investigates Adequacy of Pri..
BU
2021ACCELERON PHARMA : Avoro Capital Believes Proposed Acquisition of Acceleron Pharma by Merc..
BU
2021ACCELERON PHARMA : Merck spends $11.5B for Acceleron, possible blockbuster drug
AQ
2021ACCELERON PHARMA : REBLOZYL® (luspatercept-aamt) is a First-In-Class Erythroid Maturation ..
PU
2021ACCELERON PHARMA INC : Entry into a Material Definitive Agreement, Other Events, Financial..
AQ
2021Kraton, Hess rise; Apple, Moderna fall
AQ
2021ACCELERON PHARMA : Management's Discussion and Analysis of Financial Condition and Results..
AQ
2021ACCELERON : Q2 Earnings Snapshot
AQ
2021ACCELERON PHARMA : Reports Second Quarter 2021 Financial Results
BU
2021ACCELERON PHARMA : Results of Operations and Financial Condition (Form 8-K)
PU
2021ACCELERON PHARMA INC : Results of Operations and Financial Condition (form 8-K)
AQ
2021ACCELERON PHARMA : Announces Second Quarter 2021 REBLOZYL® Net Sales
BU
2021ACCELERON PHARMA : to Webcast Second Quarter 2021 Financial Results on August 5, 2021
BU
2021ACCELERON PHARMA INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8..
AQ
2021ACCELERON PHARMA : Research & Development Day 2021
PU
2021ACCELERON PHARMA INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
2021ACCELERON PHARMA : Reblozyl was generally well tolerated and improvements in hemoglobin co..
PU
2021ACCELERON PHARMA INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021ACCELERON PHARMA : to Host Virtual Research and Development (R&D) Day on June 22, 2021
BU
2021ACCELERON PHARMA : ATS 2021 International Conference
PU
2021ACCELERON PHARMA : Data presented show maintained or improved responses in multiple effica..
PU
2021ACCELERON PHARMA INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021ACCELERON PHARMA : For The First Time, FDA Cites Sponsor For Failure To Submit Clinical Tr..
AQ
2021ACCELERON PHARMA : Presents Preliminary Data from the SPECTRA Phase 2 Trial of Sotatercept..
BU
2021ACCELERON PHARMA : Presents Interim Results from the Open-label Extension of the PULSAR Ph..
BU
2021ACCELERON PHARMA : Announces Presentations on REBLOZYL® (luspatercept-aamt) at the 2021 Eu..
BU
2021ACCELERON PHARMA : to Host Conference Call and Webcast to Review Clinical Trial Updates, P..
BU
2021CLINICAL TRIALS : Does FDA's Notice To Acceleron Signal A New Era Of Enforcement For Resul..
AQ
2021ACCELERON PHARMA : Q1 Earnings Call
PU
2021ACCELERON PHARMA : REBLOZYL, the first and only erythroid maturation agent, was approved b..
PU
2021ACCELERON : Q1 Earnings Snapshot
AQ
2021ACCELERON PHARMA : Management's Discussion and Analysis of Financial Condition and Results..
AQ
2021ACCELERON PHARMA : Reports First Quarter 2021 Financial Results
BU
2021ACCELERON PHARMA INC : Results of Operations and Financial Condition (form 8-K)
AQ
2021ACCELERON PHARMA : Results of Operations and Financial Condition
PU
2021ACCELERON PHARMA : Announces First Quarter 2021 REBLOZYL® Net Sales
BU
2021ACCELERON PHARMA : receives FDA Notice of Noncompliance
AQ
2021ACCELERON PHARMA : to Webcast First Quarter 2021 Financial Results on May 6, 2021
BU
2021ACCELERON PHARMA INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021ACCELERON PHARMA : Announces Clinical Trial Updates, Preclinical Presentations on Sotaterc..
BU
2021ACCELERON PHARMA : New England Journal of Medicine Publishes Results of the PULSAR Phase 2..
BU
2021ACCELERON : 4Q Earnings Snapshot
AQ
2021ACCELERON PHARMA : Management's Discussion and Analysis of Financial Condition and Results..
AQ
2021ACCELERON PHARMA : Reports Fourth Quarter and Full Year 2020 Financial Results
BU
2021ACCELERON PHARMA : to Participate in Two Upcoming Healthcare Investor Conferences
BU
2021ACCELERON PHARMA : to Webcast Fourth Quarter and Full Year 2020 Financial Results on Febru..
BU
2021ACCELERON PHARMA : Health Canada Approves REBLOZYL® (luspatercept), New Class of Treatment..
BU
2021ACCELERON PHARMA INC : Results of Operations and Financial Condition (form 8-K)
AQ
2021ACCELERON PHARMA : Announces Fourth Quarter and Full Year 2020 REBLOZYL® Net Sales
BU
2021IMARA : Announces the Appointment of Kenneth Attie M.D. as Chief Medical Officer
AQ
2021ACCELERON PHARMA INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8..
AQ
2021ACCELERON PHARMA : to Participate in the 39th Annual J.P. Morgan Healthcare Conference on ..
BU
2020ACCELERON PHARMA : Receives Orphan Designation from the European Commission (EC) for Sotat..
BU
2020ACCELERON PHARMA : Receives FDA Orphan Drug Designation for ACE-1334 for the Treatment of ..
BU
2020ACCELERON PHARMA : Presents New Data from the PULSAR Phase 2 Trial, Preclinical Research o..
AQ
2020ACCELERON PHARMA : Presents Preliminary Interim Data from the SPECTRA Phase 2 Trial of Sot..
AQ
2020ACCELERON PHARMA INC : Regulation FD Disclosure, Other Events, Financial Statements and Ex..
AQ
2020ACCELERON PHARMA : Presents Preliminary Interim Data from the SPECTRA Phase 2 Trial of Sot..
BU
2020ACCELERON PHARMA : Presents New Data from the PULSAR Phase 2 Trial, Preclinical Research o..
BU
2020ACCELERON PHARMA : Announces Clinical Trial Updates, Preclinical Presentation on Sotaterce..
BU
2020ACCELERON : 3Q Earnings Snapshot
AQ
2020ACCELERON PHARMA : Management's Discussion and Analysis of Financial Condition and Results..
AQ
1  2  3  4  5  6Volgende